Healthcare & Life Sciences
Minoryx
Spain
aliveseries-b
series-b
Stage
1
Investors
About
Minoryx is a clinical-stage biotechnology company developing treatments for orphan central nervous system diseases, with its lead drug candidate MIN-102 in clinical trials for X-linked Adrenoleukodystrophy and Friedreich’s Ataxia. The company operates in Spain and Belgium.
Explore Minoryx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.